Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in Steroid Dependent Chronic Graft-Versus-Host Disease
NCT04212416Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Sep 2020
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of leflunomide in chronic graft-versus-host disease (cGVHD), sponsored by City of Hope. Primary endpoint: Dose limiting toxicity up to 28 days. Started Sep 2020; status: active, not recruiting.
02
Drugs
leflunomide
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04212416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04212416.